Last reviewed · How we verify

Bupivacaine in epidural catheter

Odense University Hospital · FDA-approved active Small molecule

Bupivacaine blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia.

Bupivacaine blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Epidural anesthesia and analgesia for surgical procedures, Epidural analgesia for labor and delivery, Postoperative pain management via epidural catheter.

At a glance

Generic nameBupivacaine in epidural catheter
SponsorOdense University Hospital
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that penetrates nerve sheaths and reversibly binds to sodium channels on the inner surface of nerve cell membranes. By blocking sodium influx, it prevents depolarization and conduction of nerve impulses in the area of administration. When delivered via epidural catheter, it provides regional anesthesia and analgesia to the lower body and lower extremities.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: